Lung Cancer Minimal Residual Disease Detection Using an Integrated cfDNA and cfRNA Approach

Purpose and goal

We aim to deliver LUMINA, a Minimal Residual Disease (MRD) detection platform based on multi-omics biomarkers for non-small cell lung cancer (NSCLC) using liquid biopsies. LUMINA will be able to accurately predict recurrence risk in patients with stage I-III that are treated with a curative intent. Our strategy relies on combining cell free DNA and RNA-based biomarkers with an AI/ML-based software, delivering >95% sensitivity and specificity for MRD prediction.

Expected effects and result

By providing a more precise diagnostic tool, the project and the software developed within aim to significantly improve clinical decision-making and patient outcomes, reducing the risks of recurrence and optimizing treatment strategies.

Planned approach and implementation

The project will focus on optimization of cfDNA analysis using biobanked samples and patient samples prospectively collected. Additionally the Standard Operating Procedures (SOP) for WGS and Whole Transcriptome Sequencing (WTS) will be finalized. The mutation calling pipeline of Oncodia that has been established using tissue biopsy samples, will be optimized for liquid biopsy samples, enabling the integration of the cfDNA and cfRNA approaches for multi-omic MRD prediction.